Favorable outcomes of patients with sickle cell disease hospitalized due to COVID‑19: A report of three cases
Open Access
- 21 March 2022
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 23 (5) , 1-7
Abstract
Sickle cell disease (SCD) is one of the most frequent and severe monogenic disorders, affecting millions of individuals worldwide. SCD represents a fatal hematological illness, characterized by veno‑occlusive events and hemolytic anemia. Hemolytic anemia is caused by abnormal sickle‑shaped erythrocytes, which induce parenchymal destruction and persistent organ damage, resulting in considerable morbidity and mortality. During the coronavirus disease 2019 (COVID‑19) pandemic, patients with SCD were characterized as a ‘high‑risk’ group due to their compromised immune system, caused by functional hyposplenism, as well as systemic vasculopathy. COVID‑19 is characterized by endothelial damage and a procoagulant condition. The present study describes the clinical features, management and outcomes of 3 patients with SCD who were hospitalized due to COVID‑19, who all had favorable outcomes despite the complications.Keywords
This publication has 28 references indexed in Scilit:
- Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the pastJournal of Clinical Virology, 2020
- COVID‐19 infection in patients with sickle cell diseaseBritish Journal of Haematology, 2020
- COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patientAmerican Journal of Hematology, 2020
- Sickle cell diseaseThe Lancet, 2017
- A global perspective on sickle cell diseasePediatric Blood & Cancer, 2012
- Evidence-based management of sickle cell disease in the emergency department.2011
- Acute chest syndrome: sickle cell diseaseEuropean Journal of Haematology, 2011
- Effects of race and ethnicity on the incidence of venous thromboembolismThrombosis Research, 2009
- Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodiesGlycobiology, 2008
- Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell DiseaseNew England Journal of Medicine, 2000